MX2022001380A - Anticuerpos de fcrn y metodos de uso de los mismos. - Google Patents

Anticuerpos de fcrn y metodos de uso de los mismos.

Info

Publication number
MX2022001380A
MX2022001380A MX2022001380A MX2022001380A MX2022001380A MX 2022001380 A MX2022001380 A MX 2022001380A MX 2022001380 A MX2022001380 A MX 2022001380A MX 2022001380 A MX2022001380 A MX 2022001380A MX 2022001380 A MX2022001380 A MX 2022001380A
Authority
MX
Mexico
Prior art keywords
subject
methods
fcrn
antibodies
block
Prior art date
Application number
MX2022001380A
Other languages
English (en)
Inventor
Santiago Arroyo
William Denney
Original Assignee
Momenta Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Momenta Pharmaceuticals Inc filed Critical Momenta Pharmaceuticals Inc
Publication of MX2022001380A publication Critical patent/MX2022001380A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

Se describen métodos para dosificación intravenosa de anticuerpos a receptor Fc neonatal humano (FcRn); los anticuerpos anti-FcRn son útiles, por ejemplo, para promover eliminación de autoanticuerpos en un sujeto, para suprimir presentación de antígeno en un sujeto, para bloquear una respuesta inmune, por ejemplo, bloquear una activación basada en complejos inmunes de la respuesta inmune en un sujeto, o para tratar enfermedades inmunológicas (por ejemplo, enfermedades autoinmunes) en un sujeto.
MX2022001380A 2019-08-01 2020-08-03 Anticuerpos de fcrn y metodos de uso de los mismos. MX2022001380A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962881897P 2019-08-01 2019-08-01
PCT/US2020/044731 WO2021022249A1 (en) 2019-08-01 2020-08-03 Fcrn antibodies and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2022001380A true MX2022001380A (es) 2022-03-25

Family

ID=74229292

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022001380A MX2022001380A (es) 2019-08-01 2020-08-03 Anticuerpos de fcrn y metodos de uso de los mismos.

Country Status (8)

Country Link
US (1) US20220259308A1 (es)
EP (1) EP4007605A4 (es)
JP (1) JP2022542430A (es)
CN (1) CN114630678A (es)
AU (1) AU2020319897A1 (es)
CA (1) CA3148826A1 (es)
MX (1) MX2022001380A (es)
WO (1) WO2021022249A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018386193A1 (en) 2017-12-13 2020-06-25 Momenta Pharmaceuticals, Inc. FcRn antibodies and methods of use thereof
EP4240417A1 (en) * 2020-11-06 2023-09-13 Momenta Pharmaceuticals, Inc. Fcrn antibodies and methods of use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7662928B2 (en) * 2003-08-08 2010-02-16 The Research Foundation Of State University Of New York Anti-FcRn antibodies for treatment of auto/allo immune conditions
KR101837329B1 (ko) * 2008-04-25 2018-03-09 다이액스 코포레이션 Ｆｃｒｎ에 대한 항체 및 이들의 용도
GB201208370D0 (en) * 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
GB201413240D0 (en) * 2014-07-25 2014-09-10 Hansa Medical Ab Method
LT3250610T (lt) * 2015-01-30 2023-09-25 Momenta Pharmaceuticals, Inc. Fcrn antikūnai ir jų panaudojimo būdai
SG11201900813RA (en) * 2016-07-29 2019-02-27 Momenta Pharmaceuticals Inc Fcrn antibodies and methods of use thereof
AU2018386193A1 (en) * 2017-12-13 2020-06-25 Momenta Pharmaceuticals, Inc. FcRn antibodies and methods of use thereof
KR20210105873A (ko) * 2018-07-20 2021-08-27 모멘타 파머슈티컬스 인코포레이티드 Fcrn 항체 조성물
EP4087875A1 (en) * 2020-01-08 2022-11-16 Argenx BV Methods for treating pemphigus disorders
JP2023531451A (ja) * 2020-06-17 2023-07-24 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 遺伝子療法患者の治療のための組成物及び方法

Also Published As

Publication number Publication date
WO2021022249A1 (en) 2021-02-04
CN114630678A (zh) 2022-06-14
US20220259308A1 (en) 2022-08-18
EP4007605A4 (en) 2023-08-16
JP2022542430A (ja) 2022-10-03
CA3148826A1 (en) 2021-02-04
EP4007605A1 (en) 2022-06-08
AU2020319897A1 (en) 2022-02-24

Similar Documents

Publication Publication Date Title
EP4286011A3 (en) Fcrn antibodies and methods of use thereof
EP4282487A3 (en) Fcrn antibodies and methods of use thereof
AU2018386193A8 (en) FcRn antibodies and methods of use thereof
AU2015255979B2 (en) Using B-cell-targeting antigen IgG fusion as tolerogenic protein therapy for treating adverse immune responses
PH12021550802A1 (en) Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof
PH12020552018A1 (en) Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
PH12019500545A1 (en) Cd3 binding antibodies
MX2019004692A (es) Anticuerpos 4-1bb anti-humano y usos de los mismos.
NZ751246A (en) Anti-tim-3 antibodies and use thereof
MX2021005193A (es) Anticuerpo que se une a fcrn para tratar enfermedades autoinmunes.
MX2018016404A (es) Anticuerpos de union a cd3.
MX2020006715A (es) Anticuerpos especificos del heterodimero de cd3-delta/epsilon.
EA201790961A1 (ru) Перенацеливающие cd3/cd38 t-клетки гетеродимерные иммуноглобулины и способы их получения
PH12019502763A1 (en) Anti-human papillomavirus (hpv) antigen-binding proteins and methods of use thereof
NZ719654A (en) Interleukin-2 fusion proteins and uses thereof
EA201890297A1 (ru) Антитело к cd154, обладающее улучшенными характеристиками связывания, функциональности и безопасности, и его применение в иммунотерапии у человека
EA201290589A1 (ru) Cd127-связывающие белки
MX2022001380A (es) Anticuerpos de fcrn y metodos de uso de los mismos.
MX2020010094A (es) Kir3dl3 como receptor de hhla2, anticuerpos anti-hhla2 y usos de estos.
WO2020136145A3 (en) Leucocyte immunoglobulin-like receptor 2 neutralizing antibodies
PH12020552006A1 (en) Antibodies specific for cd3 and uses thereof
MX2021002208A (es) Regimenes de dosificacion de la proteina de fusion de fc y dominio extracelular del cd80.
MX2020008730A (es) Regímenes de dosificación de anticuerpo b7-h4.
MX2021004226A (es) Terapia combinada contra el cáncer.
EA202091918A1 (ru) Car-t клетки и аутоиммунные заболевания